Speakers

Industry voices, not vendor pitches

Operators from leading VAMs and 505(b)(2) companies across the US and EU — regulatory leads, BD professionals, R&D heads and market-access experts.

Confirmed 12 speakers

Ana Gavaldá

Annion

Conference chair · Introduction to VAMs / 505(b)(2) · Value proposition

Ana Caterina Pinto

Bluepharma

Portfolio of VAM / 505(b)(2) · The Bluepharma experience · Portfolio round table (lead)

Rosanne d'Alessio

Valdiano

Non-clinical requirements · Business strategy · Licensing round table (lead)

Carlos Rodriguez

Polpharma

Bridging EMA and FDA · Licensing round table

James Burt

ProductLife

Market access — Europe · Market-access round table

Hans Platteeuw

Galenicap / Neuraxpharm

Repurposing of drugs · Market-access round table

Toni Santamaria

Adalvo

Patent challenges — IP strategies for added-value medicines

Irene Casalprim

Adalvo

Patent challenges — IP strategies for added-value medicines

Victor Perez

Solitek

A Second Life — solid-form engineering for old drugs

Alba Córdoba Insensé, PhD

Nanomol

Nanomedicine development — targeted delivery & controlled release

Kai Tittmann

University

Humanized biological drugs

Paolo Raddani

Ziblets

Lyophilised tablets

To be confirmed 5 speakers

Angela Drew

tbc

Regulatory & clinical requirements — US

Granzer

tbc

Regulatory & clinical requirements — EU

Marta Huguet

tbc

Portfolio round table

Dina Ferreira

tbc

Portfolio round table

Gosha

tbc

Portfolio round table

Want to speak at HYBRIDGE?

We're finalising a small number of speaking slots. If you're working on a notable VAM or 505(b)(2) programme and would like to share it with the room, get in touch.

Propose a talk